Application of Manganese oxide (MnO) nanoparticles in multimodal molecular imaging and cancer therapy: A review

Contrast agents (CAs) play a critical role in high-resolution magnetic resonance imaging (MRI) applications to enhance the low intrinsic sensitivity of MRI. Manganese oxide nanoparticles (MnO) have gotten developing consideration as substitute spin-lattice (T1) MRI CAs as a result of the Gd-based CAs which are related with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide NPs. In this review, previous developments in the usage of MnO nanoparticles as MRI CAs for cancer theranostic applications such as developments in toxicological properties, distribution and tumor microenvironment (TME)-responsive biomaterials were reviewed. A literature search was accomplished to discover distributed research that elaborates the use of MnO in multimodal imaging and therapy. In the current study, the electronic search including PubMed/Medline, Embase, ProQuest, Scopus, Cochrane and Google Scholar was performed dependent on Mesh key words. CAs can significantly improve the imaging contrast among the lesions and normal tissues. In this study we generally concentrate on typical advancements of MnO nanoparticles about properties, bimodal or multimodal imaging, and therapy. Numerous researches have demonstrated MnO-based nano structure produce considerable biocompatibility with the lack of cytotoxicity. Therefore, remarkable features improved photothermal therapy, chemotherapy and Chemo dynamic therapy.